The antitumor drug mitindomide (NSC 284356) was shown to inhibit the decatenation activity of human and Chinese hamster ovary (CHO) topoisomerase II [DNA topoisomerase (ATP-hydrolyzing), EC 5.99.1.1]. Mitindomide did not induce the formation of topoisomerase II-DNA covalent cleavable complexes in CHO cells. These results taken together indicate that mitindomide is a catalytic/noncleavable complex-forming-type inhibitor of topoisomerase II. The growth inhibitory effects of mitindomide and dexrazoxane toward a sensitive parent CHO cell line and the dexrazoxane-resistant DZR cell line, which is highly (500-fold) resistant to the bisdioxopiperazine dexrazoxane, were measured. The DZR cell line was shown to be 30-fold cross-resistant to mitindomide. Mitindomide, like dexrazoxane, was shown to inhibit cleavable complex formation by the topoisomerase II poison etoposide. The attenuated inhibition of etoposide-induced cleavable complexes in DZR compared with CHO cells was, likewise, very similar for dexrazoxane and mitindomide. Together these results suggest that mitindomide acts at the same site on topoisomerase II as does dexrazoxane and other bisdioxopiperazines. Various molecular parameters obtained by molecular modeling were compared for mitindomide and dexrazoxane. Mitindomide, which is conformationally very rigid, has highly coplanar imide rings, as does dexrazoxane in the solid state. Other molecular parameters, such as the imide nitrogen-to-imide nitrogen bond distances, and polar and nonpolar surface areas were also very similar. Thus, it is concluded that mitindomide exerts its antitumor effects through its inhibition of topoisomerase II by binding to the bisdioxopiperazine binding site.
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Mitindomide (NSC 284356) ( Fig. 1 ) and a number of its analogs have been shown to have good antitumor activity (1) (2) (3) . Even though mitindomide has been shown to slowly (over 12 hr) promote DNA-interstrand cross-linking (4), the mechanism by which mitindomide or its analogs exert their antitumor effects has never been identified. Problems with low aqueous solubility of mitindomide (3, 5, 6) led to the development of a number of more soluble N-substituted analogs (3, 4, (7) (8) (9) , some of which also displayed good antitumor activity. The N-substituted mitindomide analog fetindomide (NSC 373965) has been shown (10) to hydrolyze to mitindomide, suggesting that mitindomide is the active form of fetindomide.
The bisdioxopiperazine dexrazoxane ( Fig. 1) , like mitindomide, is also a bis imide. We and others have shown that the bisdioxopiperazines dexrazoxane (ICRF-187; Zinecard, ADR-529) (Fig. 1) , ICRF-159 (razoxane, the racemic form of dexrazoxane), and ICRF-193 ( Fig. 1 ) are strong inhibitors of mammalian topoisomerase II (11, 12) . Razoxane was developed originally as an antitumor agent (13) . Dexrazoxane is, however, now clinically used for the prevention of doxorubicininduced cardiotoxicity (14) , and presumably acts through its EDTA-like hydrolysis product (15) by inhibiting iron-dependent oxygen free radical formation.
Topoisomerase II alters DNA topology by catalyzing the passing of an intact DNA double helix through a transient double-stranded break made in a second helix (16, 17) . A number of antitumor drugs, including the anthracycline doxorubicin, the epipodophyllotoxins etoposide and teniposide, and amsacrine are thought to be cytotoxic by virtue of their ability to stabilize a covalent topoisomerase II-DNA intermediate (the cleavable complex) (16) . However, the bisdioxopiperazines (11) , like several other cytotoxic topoisomerase II inhibitors, including suramin (18) , merbarone (19) , and the anthracycline aclarubicin (20) , have been shown to inhibit topoisomerase II (11, 21) without promoting cleavable complex formation. The bisdioxopiperazines can, in fact, reduce protein-DNA cross-links induced by etoposide, amsacrine, daunorubicin, and doxorubicin (11, (21) (22) (23) , as well as reducing the growth-inhibitory effects of doxorubicin and daunorubicin (22, 24) . Because mitindomide has some structural features that are similar to dexrazoxane (Fig. 1) , and because of the earlier demonstration of very significant crossresistance to mitindomide by six independent cell lines with induced resistance to ICRF-159 (25, 26) , a common mechanism of action seemed likely. Thus, it was decided to determine whether mitindomide also exerted its antitumor effects through the inhibition of topoisomerase II.
Materials and Methods
Drugs and chemicals. Dexrazoxane (Zinecard, ICRF-187), was a gift from Pharmacia & Upjohn (Columbus, OH). Mitindomide (NSC-284356) was obtained from the National Cancer Institute, (Bethesda, MD). Etoposide was obtained from Bristol-Myers Squibb (Wallingford, CT). kDNA and chromatographically purified, recombinant p170 human topoisomerase II␣ (expressed in yeast) were obtained from Topogen (Columbus, OH). Agarose (Ultra Pure) was obtained from Gibco BRL (Burlington, Canada).
Cell culture and cytotoxicity assay. CHO cells (type AA8) were obtained from the American Type Culture Collection (Rockville, MD). The dexrazoxane-resistant DZR cells, derived from the parent CHO cells, were selected in the presence of increasing concentrations of dexrazoxane over a period of 4 months and have been described elsewhere (21) . DZR cells used in the experiments reported here had not been exposed to dexrazoxane for at least several months and showed no loss in resistance. Both cell lines were grown in ␣-minimum essential medium (Gibco BRL) containing 20 mM HEPES (Sigma, St. Louis, MO), 100 units/ml penicillin G, 100 g/ml streptomycin, 10% fetal bovine serum (Gibco BRL) in an atmosphere of 5% CO 2 and 95% air at 37°(pH 7.4) as described previously (12, 21) . For the measurement of cell growth inhibition by MTT assay (12, 21) , cells in exponential growth were harvested and seeded either at 2000 cells/ well (CHO) or 5000 cells/well (DZR) in 96-well microtiter plates (100 l/well) and allowed to attach for 24 hr. Drugs were dissolved either in ␣-minimum essential medium (dexrazoxane), or in either DMSO (mitindomide) or in NaOH (mitindomide, two equivalents to titrate the two imide hydrogens) with equivalent results, and were added to give a final volume of 200 l/well. When DMSO was used, due to solubility problems, the final concentration of DMSO did not exceed 0.5% (v/v). This amount of DMSO was shown, through the use of appropriate controls, to have no significant effect on cell growth. When NaOH was used, an equivalent amount of HCl was added to ensure that the pH did not change. The cells were then allowed to grow for a further 72 hr. Typically, six replicates were measured at each drug concentration. The IC 50 values for growth inhibition were obtained from a nonlinear least squares fit (SigmaPlot, Jandel, San Rafael CA) of the absorbance-drug concentration data to either a three-or four-parameter logistic equation as appropriate.
Topoisomerase II inhibition gel assay. The inhibition of topoisomerase II activity was measured by the ATP-dependent decatenation of kDNA (27) . Reactions were carried out in 20 l and contained 50 mM Tris⅐HCl, pH 8, 120 mM KCl, 10 mM MgCl 2 , 0.5 mM ATP, 0.5 mM dithiothreitol, 30 g/ml bovine serum albumin, 200-300 ng of kDNA, and topoisomerase II. The amount of topoisomerase II (approximately 1 unit) was adjusted in preliminary experiments to decatenate approximately 80-90% of the kDNA under our assay conditions. The reactions were incubated at 37°for 30 min and terminated by the addition of 5 l of a stop buffer containing 5% (w/v) N-lauroylsarcosine, 0.125% (w/v) bromphenol blue, and 25% (v/v) glycerol. The decatenated reaction products were separated by agarose gel electrophoresis. Both the agarose gel (1% w/v) and the running buffer both contained 0.2 g/ml of the DNA stain ethidium bromide. The gels were run at 100 V for about 40 min and after destaining were photographed by Polaroid type 667 film under UV transillumination. Authentic decatenated kDNA and linear kDNA (Topogen Inc.) were run as controls to identify decatenated kDNA. Controls were also run in the absence of ATP (for nuclease activity, none found) and DMSO. The photographs were scanned with a Hewlett-Packard ScanJet 4P scanner (Hewlett Packard, Avondale, PA) and the 256-grey-scale digitized images were analyzed using SigmaGel (Jandel Scientific). The amount of decatenated nicked, open circular kDNA formed (identified as NOC in Fig. 2 ) was quantified by measuring the integrated intensity of the band. Topoisomerase II-containing nuclear extracts, used in some experiments, were prepared from CHO cells in exponential growth, as described previously (12) .
Topoisomerase II-DNA covalent complexes. Topoisomerase II-DNA covalent complex formation in intact cells was measured as described previously (28) . Mid-log growth CHO and DZR cells were labeled for 24 hr with 0.5 Ci/ml [methyl-
3 H]thymidine (0.5 Ci/mmol) and 0.1 Ci/ml [ 14 C]leucine (318 mCi/mmol) in Dulbecco's modified Eagle medium containing 7.5% (v/v) iron-supplemented calf serum. Cells were then pelleted and resuspended in fresh Dulbecco's modified Eagle medium/7.5% calf serum and incubated for 1 hr at 37°. Cells were pelleted and resuspended in buffer, pH 7.4, containing 115 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 5 mM NaH 2 PO 4 , 25 mM HEPES, and 10 mM glucose at 37°at a final cell density of 1.0 ϫ 10 6 cells/ml for experimentation. Cells were then incubated with various concentrations of etoposide alone or in combination with dexrazoxane or mitindomide. Reactions were stopped by adding 1 ml of cell suspension to 10 ml of ice-cold phosphate-buffered saline. Cells were then pelleted, lysed, cellular DNA sheared, and protein-DNA complexes precipitated with SDS and KCl as described previously (28) . Topoisomerase II-DNA covalent complexes were quantified by scintillation counting, and [ 3 H]DNA was normalized to cell number using the co-precipitated 
Results
Inhibition of topoisomerase II by mitindomide and dexrazoxane. As shown by the gel decatenation results in Figs. 2 and 3 using human p170 topoisomerase II, mitindomide inhibited the topoisomerase II-catalyzed decatenation of kDNA. kDNA consists of an extensive network of many interlocked (catenated) circular DNA molecules. Topoisomerase II, which catalyzes strand-passing of double-stranded DNA, decatenates the kDNA yielding 2.5-kilobase relaxed decatenated kDNA monomers that run much faster on the gel than the catenated kDNA substrate (27) . The covalently closed circular decatenated kDNA (CC in Fig. 2 ) is produced by the action of topoisomerase II on intact kDNA substrate.
The nicked, open circular decatenated kDNA (NOC in Fig. 2 ) is produced by the action of topoisomerase II on nicked kDNA substrate formed during the isolation of kDNA. To determine whether there was any difference in mitindomide-or dexrazoxane-mediated inhibition of topoisomerase II from CHO cells compared with human cells, inhibition assays were also carried out on nuclear extracts obtained from CHO cells. The results shown in Table 1 indicate that the topoisomerase II in CHO nuclear extracts and purified human p170 topoisomerase II are inhibited to about the same degree. The IC 50 -value for mitindomide is about 20 times larger than for dexrazoxane for both human topoisomerase II and CHO nuclear extract topoisomerase II.
Cross-resistance of mitindomide toward dexrazoxane-resistant DZR cells. To establish whether mitindomide inhibits topoisomerase II at the same site, or by the same mechanism as dexrazoxane, the growth-inhibitory effects of mitindomide in a dexrazoxane-resistant CHO cell line (DZR) were measured. We showed previously that a number of other bisdioxopiperazines exhibited significant cross-resistance in DZR cells compared with CHO cells (21) . As shown in Fig. 4 and the IC 50 values in Table 1 , mitindomide exhibited significantly less growth inhibitory effects toward DZR cells compared with the parent CHO cells. Because of the high cross-resistance of the DZR cell line toward mitindomide, it was difficult to determine accurately the IC 50 value for mitindomide in the DZR cell line. Up to the aqueous solubil- molpharm.aspetjournals.org ity limit of mitindomide (Յ1000 M), only a maximum of 15% growth inhibition of the DZR cells was seen (Fig. 4) . Thus, the resistance factor for mitindomide of at least 30 is comparable to that for ICRF-193 (Table 1) of 18, and other bisdioxopiperazines (21) . These results suggest strongly that mitindomide binds to the same site on topoisomerase II as do the bisdioxopiperazines.
Lack of covalent cleavable complex formation by mitindomide. A number of topoisomerase II poisons, including the anthracycline doxorubicin, the epipodophyllotoxins etoposide and teniposide, and amsacrine, are thought to be cytotoxic through their ability to stabilize a covalent topoisomerase II-DNA intermediate (the cleavable complex) (16) . The bisdioxopiperazines, however, are catalytic or noncleavable complex forming inhibitors (11) that inhibit topoisomerase II without promoting cleavable complex formation. Thus, cleavable complex formation was measured in CHO cells to Inhibition of etoposide-induced topoisomerase II-DNA covalent complexes by mitindomide. We showed previously that dexrazoxane was able to significantly inhibit etoposide-induced cleavable complex formation in CHO cells (21) . We also showed that dexrazoxane was effective in inhibiting etoposide-induced cleavable complex formation in K562 and etoposide-resistant K/VP.5 cells (23) . The bisdioxopiperazine ICRF-193 has also been shown to reduce etoposide-induced cleavable complex formation (30) . Thus, if mitindomide acts like the bisdioxopiperazines, it should also be able to reduce etoposide-induced cleavable complex formation. As shown in Fig. 6a , mitindomide inhibits etoposideinduced cleavable complex formation in a concentration-dependent manner in CHO cells. The results of Fig. 6a show that 200 M mitindomide significantly ( p ϭ 0.024, n ϭ 3) decreases etoposide-induced cleavable complex formation in CHO cells, but not in DZR cells ( p ϭ 0.27, n ϭ 4). This attenuated inhibition of etoposide-induced cleavable complex formation in DZR cells, compared with CHO cells, was also seen previously with dexrazoxane (21) . Thus, mitindomide acts similarly to dexrazoxane, not only in its ability to inhibit etoposide-induced cleavable complex formation, but also because it has a decreased ability to inhibit etoposide-induced cleavable complex formation in DZR cells compared with CHO cells. These results also suggest strongly that mitindomide acts on the same site on topoisomerase II, and by the same mechanism as dexrazoxane.
Molecular modeling of mitindomide and dexrazoxane. Because mitindomide and dexrazoxane are both bis imides with some structural similarities, the structures of the two compounds were compared using molecular modeling to determine what structural features the two drugs have in common that are essential for their topoisomerase II-inhibitory activity. The modeling of these compounds was aided by the x-ray crystal structures of dexrazoxane (31) , an N-substituted analog of mitindomide (32) , and of a one-ring-opened mitindomide derivative (33) . Molecular mechanics minimization of a mitindomide structure obtained from the x-ray structure of the N-substituted analog of mitindomide (32) gave a structure very close (root mean square deviation for all common heteroatoms and hydrogens was 0.09 Å) to the N-substituted mitindomide. Thus, parameters derived from the mitindomide structure obtained from molecular modeling can be used with confidence. The structure shown for dexrazoxane was, likewise, obtained from the x-ray crystal structure of dexrazoxane (31) . Dexrazoxane is a conformationally flexible molecule compared with the structurally rigid mitindomide. In the crystal, dexrazoxane is H-bonded through the imide hydrogen atom and one carbonyl oxygen atom to an adjacent dexrazoxane molecule in a head-to-tail arrangement (31) . The conformation of dexrazoxane in the crystal is very close to the energetically most stable structure, as the rotational energy plots (data not shown) for rotation about either the nitrogen-main chain carbon atom or the two main chain carbon atoms were at a minima for the structure shown in Fig. 7 . Data for the dexrazoxane analog ICRF-193 (Fig. 1) , which is the most potent known bisdioxopiperazine topoisomerase II inhibitor (12) , are also included in Table 2 for comparison. The structure of mitindomide and dexrazoxane are compared in Fig. 7 . It can be seen from Fig. 7 and the data of Table 2 that both structures have a number of common structural features. The most striking feature in common is the coplanarity (7.3 and 1.3°on mitindomide and dexrazoxane, respectively) of the two imide-containing rings on each of these molecules. Also the imide nitrogen-to-imide nitrogen bond distance in mitindomide is only slightly shorter (7.8 compared with 9.0 Å) than in dexrazoxane. Although there is a high degree of coplanarity in each molecule, the two planes are offset from each other in each molecule. This offset, measured from the distance the nitrogen of the distal imide ring in each molecule lies above the plane formed by the first imide ring, is very similar (3.0 and 3.7 Å for mitindomide and dexrazoxane, respectively). The molecular volumes and the total surface areas of dexrazoxane and ICRF-193 are only slightly larger than for mitindomide (Table 2) . Similarly, the van der Waals polar surface area of each of these molecules is also very close ( Table 2) .
Discussion
The growth-inhibitory effect of mitindomide with an IC 50 value of 69 M toward CHO cells determined in this study (Table 1) compares with an IC 50 value of 16 M for a different CHO cell line (25) , and 73 M for L1210 leukemia cells (6) . We have shown, using a kDNA decatenation assay (Fig. 2) , that mitindomide inhibits the catalytic activity of topoisomerase II. We further showed that mitindomide inhibits topoisomerase II without increasing topoisomerase II-DNA covalent cleavable complex formation (Figs. 5 and 6b ). This latter result establishes that mitindomide is a catalytic (or noncleavable complex-forming) type of topoisomerase II inhibitor. Other known catalytic inhibitors include the bisdiox- opiperazines (11, 12, 21) , suramin (18) , merbarone (19) , and aclarubicin (20) . Mitindomide also showed significant crossresistance (Fig. 4 and Table 1 ) to the dexrazoxane-resistant DZR cell line. This cell line has been shown to have high cross-resistance to a number of other bisdioxopiperazines, but not to the other catalytic topoisomerase II inhibitors suramin, merbarone, or aclarubicin, suggesting that the topoisomerase II has acquired point mutations that change critical regions of the enzyme required for bisdioxopiperazine binding or activity (21) . Thus, mitindomide cross-resistance in the DZR cell suggests that mitindomide binds at the same site as dexrazoxane and the other bisdioxopiperazines. We also showed that mitindomide was able to effectively reduce etoposide-induced cleavable complex formation (Fig. 6b) in a manner similar to dexrazoxane (21) . The attenuated inhibition of etoposide-induced cleavable complex formation shown for DZR compared with CHO cells (Fig. 6, b and c) closely parallels that exhibited by dexrazoxane (21) . Thus, both these results further suggest that mitindomide acts at the same site on topoisomerase II as dexrazoxane. Also consistent with our results, mitindomide has also been shown to be at least 18-fold cross-resistant (25, 26) to another bisdioxopiperazine (ICRF-159)-resistant CHO cell line (34) .
Mitindomide is conformationally a very rigid structure, unlike dexrazoxane, which can potentially adopt a large number of conformations through rotation about the two nitrogen-carbon bonds and the two carbon-carbon bonds. The two imide rings of mitindomide are highly coplanar (Table 2 and Fig. 7) . The x-ray crystal structure of dexrazoxane (31) shows that in the crystal, dexrazoxane, adopts an extended conformation ( Fig. 7) with a high degree of coplanarity between the imide rings. This conformation closely resembles that of mitindomide ( Fig. 7) with imide nitrogen-to-imide nitrogen distances and other molecular parameters being quite similar to that for dexrazoxane and ICRF-193 (Table 2) . These results suggest that dexrazoxane interacts with topoisomerase II in its extended conformation with its imide rings coplanar. Because mitindomide does not have nitrogen atoms in the central part of the molecule like dexrazoxane, we would also like to suggest that there is no absolute requirement for non-imide nitrogens of the piperazine groups in dexrazoxane for binding to topoisomerase II. A number of mitindomide analogs were tested for activity in an in vivo P-388 leukemia screen (3) and were used to define the structural features that are required for activity. Imides with shorter imide nitrogen-to-imide nitrogen bond distances than mitindomide were found to be inactive (3). We also showed previously (12) that ICRF-161, which has a 3 carbon linear alkane central chain, was both much less growth inhibitory toward CHO cells and a weaker inhibitor of topoisomerase II. In the extended conformation ICRF-161 would be expected to have an imide nitrogen-to-imide nitrogen bond distance larger than that of dexrazoxane. Thus, an imide nitrogen-toimide nitrogen bond distance of about 9 Å, which is between that seen for mitindomide and ICRF-161, may be about optimal for the inhibition of topoisomerase II. The dihydro analog of mitindomide was also active (3), indicating the lack of a requirement for the double bond in mitindomide. Although the molecular modeling studies show the strong structural similarities that exist between mitindomide and dexrazoxane, suggesting that mitindomide is a bisdioxopiperazine type topoisomerase II inhibitor, the conclusion that mitindomide inhibits topoisomerase II at the bisdioxopiperazine binding site is based mainly on our biochemical and pharmacological studies. Ball and stick structures of mitindomide (top) and dexrazoxane (bottom) are compared. The structure of mitindomide was obtained from molecular modeling using the x-ray crystal structure of an Nsubstituted mitindomide analog (32) and dexrazoxane (31) as starting points. Both molecules have imide rings that are nearly coplanar and similar imide nitrogen-to-imide nitrogen distances (7.8 and 9.0 Å for mitindomide and dexrazoxane, respectively). Only the heteroatoms are labeled.
TABLE 2 Comparison of the structural parameters of mitindomide and the bisdioxopiperazines dexrazoxane (ICRF-187) and ICRF-193
The molecular parameters were derived from molecular modeling and X-ray structures of dexrazoxane and an analog of mitindomide. Imide N-to-imide N distance, coplanarity of imide rings, and N-to-plane distance were derived from X-ray crystal structures from an N-substituted derivative of mitindomide (32) and dexrazoxane (31) and molecular modeling for ICRF-193. The imide ring plane was defined by the nitrogen imide atom and the two adjacent carbonyl carbon atoms. The coplanarity was measured by calculating the angle of the normals of the two planes to each other. Area and volume were calculated from the van der Waals surfaces by molecular modeling. Nonpolar surface area includes contributions from both unsaturated (mitindomide only) and saturated areas.
Parameter
Mitindomide Dexrazoxane Imide N-to-imide N distance (Å) 7.8 9.0 9. 
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It has been proposed that dexrazoxane and the other bisdioxopiperazines interact with topoisomerase II without forming topoisomerase II-DNA cleavable complexes (11) . It has been shown that in the presence of ATP, (Fig.  1) converts topoisomerase II to a form incapable of binding circular DNA (35) . These results were interpreted in terms of an ATP-modulated protein-clamp model (17, 36) in which ICRF-193 binds to the closed clamp form of the enzyme and prevents its conversion to the DNA-binding open-clamp form. If mitindomide is acting at the same site as the other bisdioxopiperazines, it too, would be capable of preventing the opening of the closed clamp form of the enzyme.
Our finding that mitindomide is a catalytic inhibitor of topoisomerase II may lead to the rational development of more efficacious mitindomide analogs. Mitindomide is also likely to find use as a probe of mechanism of topoisomerase II activity and the action of a number of important topoisomerase II-directed anticancer drugs. Because mitindomide does not yield an EDTA-type structure like dexrazoxane (15) , the metal chelating effects and topoisomerase II inhibitory effects on cell growth of these two drugs may be separated.
